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Treatment and prevention studies over the past decade have
enrolled patients believed to be at risk for future psychosis.
These patients were considered at risk for psychosis by virtue
of meeting research criteria derived from retrospective
accounts of the psychosis prodrome. This study evaluated
the diagnostic validity of the prospective ‘‘prodromal risk syn-
drome’’ construct. Patients assessed by the Structured Inter-
view for Prodromal Syndromes as meeting criteria of
prodromal syndromes (n 5 377) from the North American
Prodrome Longitudinal Study were compared with normal
comparison (NC, n 5 196), help-seeking comparison
(HSC, n 5 198), familial high-risk (FHR, n 5 40), and
schizotypal personality disorder (SPD, n 5 49) groups.
Comparisons weremade on variables from cross-sectional de-
mographic, symptom, functional, comorbid diagnostic, and
family history domains of assessment as well as on follow-
up outcome. Prodromal risk syndrome patients as a group
were robustly distinguished from NC subjects across all
domains and distinguished from HSC subjects and from
FHR subjects on most measures in many of these domains.
Adolescent and young adult SPD patients, while distinct from
prodromal patients on definitional grounds, were similar to
prodromals on multiple measures, consistent with SPD in
young patients possibly being an independent risk syndrome
for psychosis. The strong evidence of diagnostic validity for
the prodromal risk syndrome for first psychosis raises the
question of its evaluation for inclusion inDiagnostic and Sta-
tistical Manual of Mental Disorders (Fifth Edition).
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A prodrome has been defined as ‘‘an early or premoni-
tory manifestation of impending disease, before specific
symptoms begin,’’1 and a prodrome of schizophrenia has
been described since the time of Bleuler.2 So defined,
a prodrome for schizophrenia can be identified only in
retrospect, after the disease has been diagnosed, when
the opportunity for preventing onset is past.
‘‘The prodromal risk syndrome for psychosis’’ is a term
here applied to the condition studied using prospective
methods by researchers interested in prevention3–26
over the past decade or so. These researchers have con-
sistently described a syndrome carrying a substantial risk
of progression to full-blown psychosis in the near future
that is characterized by evolving attenuated positive symp-
toms, negative symptoms, and functional impairment.
Other terms used for this syndrome include ‘‘at-risk
mental state,’’ ‘‘ultra high risk,’’ ‘‘clinical high risk,’’
and ‘‘putative prodrome.’’ Two comprehensive reviews
of this literature have appeared fairly recently,19,27 and
the ‘‘prodromal’’ or clinical high-risk paradigm has be-
come relatively well established alongside the familial
high-risk (FHR) paradigm28,29 for investigating onset of
psychosis longitudinally. One structured interview for
prospective diagnosis of the prodromal risk syndrome
for psychosis has shown excellent diagnostic interrater
reliability,4,5,30 and 2 such interviews have shown excellent
item severity reliability within the at-risk sample.5,12,31
Despite the general consistency of this work, limita-
tions of published studies have thus far restrained confi-
dence about the validity of the prodromal risk syndrome
for psychosis as a diagnosis. These limitations have in-
cluded relatively small sample sizes, absence of appropri-
ate comparison groups, and restricted domains of
assessment. In only half of available reports are sample
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sizes of prodromal patients larger than 50.6–11,13,15,21–26
Of these, only 4 reports feature nonprodromal compar-
ison groups,6,23,24,26 and only 2 reports included more
than one domain of assessment.6,23
As a result of these limitations, the prospective diagno-
sis of patients as being in a prodromal risk syndrome for
psychosis has yet to be accepted by psychiatric profes-
sional societies, the Food and Drug Administration, or
US insurance companies. The absence of these opera-
tional hallmarks of clinical validity has in turn slowed
the development of a treatment research evidence base
that could benefit these impaired, symptomatic, at-risk
patients and their families.
The purpose of the present study was to evaluate the
construct validity of the prodromal risk syndrome for first
psychosis (hereafter also referred to as ‘‘the prodromal
patient’’ or simply as ‘‘the prodrome’’). An approach
for establishing the diagnostic validity of psychiatric
syndromes in general was outlined in a seminal 1970 article
by Robins and Guze.32 Our North American Prodrome
Longitudinal Study (NAPLS) collaboration30 permitted
application of this method to the prodromal risk syndrome
for psychosis in a large sample with multiple comparison
groups and cross-sectional demographic, symptom, func-
tional, comorbid diagnostic, and family history domains
of assessment as well as follow-up outcome.
Method
The construction of the database has been described pre-
viously.30 Briefly, 7 projects with broadly similar goals
that focused on prospectively determining the outcomes
of a prodromal diagnosis and improving prediction were
funded by National Institute of Mental Health (NIMH)
between 2000 and 2003. An eighth NIMH-funded project
was collecting a sample of well-characterized FHR sub-
jects for the analysis of psychosis risk factors. These proj-
ects were granted supplements to create a federated
database to increase sample size and statistical power
and became known collectively as NAPLS. Each site uti-
lized the Structured Interview for Prodromal Syndromes
(SIPS) to evaluate and monitor prodromal symptoms.
Detailed descriptions of SIPS symptom severity scales,
prodromal diagnostic criteria, and psychometric proper-
ties are available.4,5,33,34 Diagnostic agreement with gold
standard SIPS diagnoses was in the excellent range (j >
0.80) at each center.30 Other assessment methods varied
across site, because the projects had been conceived inde-
pendently, although there was considerable overlap as
well.30 Each site obtained institutional review board ap-
proval to contribute anonymous data.
Subjects
The 8 sites contributed data for 860 nonpsychotic sub-
jects enrolled between 1998 and 2005. These subjects
were categorized into 5 nonoverlapping groups as de-
scribed in figure 1. Briefly, prodromal patients met the
criteria for prodromal syndromes outlined in the SIPS
after clinical referral. One or more of 3 criteria had to be
met: (1) new onset or recent worsening of subsyndromal
(‘‘attenuated’’) positive psychotic symptoms, (2) very
brief periods of fully psychotic positive symptoms, or
(3) deterioration in functioning within the last year
and schizotypal personality disorder (SPD) or a having
first-degree relative with psychosis. Detailed research def-
initions of the 3 prodromal syndromes have been pub-
lished previously.4,5 Patients meeting prodrome criteria
(n = 377) were classified for the present analysis in the
prodromal analysis group without regard to whether
they also had a family history of psychosis or whether
Fig. 1.Description of SubjectGroupings. Sample sizes and overlaps
are approximately proportional to oval areas. Subjects within the
largest oval were clinically referred because of psychotic like
symptoms. Within this large group (n 5 624), subjects who met
prodrome criteria (n 5 377) are shown inside the widely outlined
oval, and subjects who met schizotypal personality disorder (SPD)
criteria are shown inside the lightly hatched oval (n 5 147). Among
the 147 schizotypal patients, 98 also met prodrome criteria (67% of
schizotypals and 26% of prodromals). The remaining clinically
referred subjects whomet neither prodrome nor schizotypal criteria
are labeled help-seeking comparison (HSC) subjects (n 5 198). The
crosshatched oval containing subjects with a definite first-degree
family history of psychosis (n 5 125) includes 40 subjects whowere
not clinically referred (familial high risk subjects, FHR, darkly
hatchedregion).Atotalof19%ofprodromals,11%ofHSCsubjects,
and 5% of the SPD analysis group had a definite first-degree family
history of psychosis (table 6). All subjects meeting prodromal
criteriawere retained in the prodromal analysis group, regardless of
schizotypal comorbidity or family history. The SPD analysis group
was restricted to schizotypal patients who did not meet prodrome
criteria,without regard to family history (n 5 49).AllHSCsubjects
were retained in the HSC analysis group, without regard to family
history. Inaddition to these subjects, 196 subjects referredashealthy
volunteers and who had no first-degree family history of psychosis
defined the normal comparison group.
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they also met SPD criteria. Prodromal patients were ex-
cluded from the defined nonoverlapping FHR and SPD
analysis groups (see below). Seven sites recruited prodro-
mal patients (table 1). Normal comparison (NC) subjects
(n = 196) were recruited as healthy volunteers by 6 sites
(table 1). Recruitment practices for NC subjects differed
somewhat across site: 5 sites used advertisements,28,35–37
2 sites Web sites,28,35 and 1 site a university registry.38
Four sites sought NC subjects with no history of psychi-
atric illness; these sites excluded subjects with any current
or lifetime Diagnostic and Statistical Manual of Mental
Disorders (DSM) diagnosis. Two sites soughtNC subjects
with no history of psychosis28; these sites permitted non-
psychotic Axis I current or lifetime DSM diagnoses. All
sites excluded subjects with first-degree family histories
of psychosis, but 4 sites permitted second-degree family
histories of psychosis,35,36,38 and 2 excluded those with
second-degree histories.28,37 Help-seeking comparison
(HSC) subjects (n = 198) are included from 6 sites. These
subjects had been clinically referred for evaluation of
symptoms that appeared potentially to qualify as
prodromal on initial telephone contact. Then, on formal
SIPS interview, these subjects did not meet prodrome
(or SPD) criteria. Usually, these subjects did not meet
prodromecriteriaoninterviewbecauseattenuatedpositive
symptoms had not begun or worsened in the past year,
although in some cases the attenuated positive
symptoms were too mild or too infrequent. Usually, the
HSC subjects did not meet SPD criteria because they
did not have symptoms in at least 5 of the 9 areas required.
FHR subjects (n = 40, from 2 sites) were nonclinical
recruits from 2 sites with a first-degree family history of
psychosis; and patients in the SPD group (n = 49, from
4 sites) met Diagnostic and Statistical Manual of Mental
Disorders (Fourth Edition) (DSM-IV) schizotypal (but
not prodrome) criteria as determined by SIPS interview.
Assessments
Subjects underwent baseline interviews at each site.
Positive, negative, disorganized, and general symptoms
(table 4) were rated using the Scale of Prodromal
Symptoms (SOPS) contained within the SIPS4,5,20,33,34
for nearly all subjects. SOPS are scaled 0–6, with exten-
sive anchors for each scale point for each symptom.
For positive symptoms, the anchor title for a rating of
zero is ‘‘none’’ and for a rating of six is ‘‘psychotic.’’
SOPS scores for some positive items were estimated
from other available instruments in 38 FHR subjects
(details on request). Functional status was assessed
with a modified Global Assessment of Functioning
(GAF) Scale,39 the Cannon-Spoor Premorbid Adjust-
ment Scale,40,41 and with new measures of social func-
tioning and instrumental role performance.42 Axis I
diagnoses were established by structured interview,
conducted by a trained interviewer whomet local reliabil-
ity standards, usually at the masters or doctoral level.
Sites consistently employed versions of the Structured
Clinical Interview for DSM-IV (SCID-IV)43 and/or the
Schedule for Affective Disorder and Schizophrenia for
School-Aged Children (K-SADS).44 The Comprehensive
Assessment of Symptoms and History (CASH)45 was
used by 3 sites for some subjects. Some sites obtained
substance diagnoses from Drake’s Alcohol and Drug
Use Scales.46 Axis II diagnoses were established using
the Structured Interview for DSM-IV Personality
Disorders,47 Diagnostic Interview forDSM-IV Personal-
ity Disorders,48 or the SCID-IV Axis II personality
disorders.49 Family psychiatric history was determined
using the Family History-Research Diagnostic Criteria
data sheet,50 the Family Interview for Genetic Studies,51
or local structured measures.
The SIPSwas readministered at 6-month intervals up to
30 months. The primary course variable was time from
baseline to conversion to psychosis. Conversion to psycho-
sis was defined according to criteria operationalized in the
SIPS. These criteria define frank psychosis as the presence
of positive symptoms of sufficient intensity that are either
seriously disorganizing or dangerous or that have been
present for a month, at least half the days, at least an
hour per day.4,5 In addition to the SIPS, another
Table 1. Numbers of Subjects by Site and Baseline Diagnosis
Baseline UNC Emory Harvard ZHH Toronto UCLA UCSD Yale Total
Prodrome 51 11 0 45 39 46 59 126 377
NC subjects 36 30 54 23 0 5 48 0 196
HSC subjects 7 58 0 57 11 0 2 63 198
FHR subjects 0 0 38 2 0 0 0 0 40
SPD subjects 0 27 0 3 0 0 3 16 49
Total 94 126 92 130 50 51 112 205 860
Note: UNC, University of North Carolina; ZHH, Zucker Hillside Hospital; UCLA, University of California, Los Angeles; UCSD,
University of California, San Diego; NC, normal comparison; HSC, help-seeking comparison; FHR, familial high risk; SPD,
schizotypal personality disorder.
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diagnostic interview (SCID-IV, K-SADS, or CASH) was
used to determineDSM-IV psychotic syndrome diagnoses
for interviewed converting cases. When possibly convert-
ing subjects could not be interviewed in person, sites estab-
lished best estimates of conversion to psychosis based on
review of hospital and other medical records and tele-
phone interviews with subjects, family members, and
members of the treatment team. When conversion to psy-
chosis was established with these methods, the DSM-IV
diagnosis was considered missing. The database was
closed to inclusion of follow-up information after
September 30, 2006.
Statistical Methods
Available data for the 5 subject groups were compared
for each measure. Because initial findings suggested de-
mographic differences in age, gender, and race across
groups, subsequent analyses employed these demo-
graphic variables as covariates. General linear models
were used for continuous measures, logistic regression
for categorical measures, and proportional hazards
models for time-to-event measures. Post hoc testing
utilized the same models and was restricted by design
to the 4 pairwise comparisons of the prodromal group
to the 4 comparison groups. When there were 0 cases
in a cell, 2 3 2 Fisher exact tests were substituted for
logistic regression. Alpha for post hoc testing was set at
a Bonferroni-corrected .0125, 2 tailed.
Previous Reports
To date there are 2 previous NAPLS publications which
use data from the same subject group. The first article,30
while largely a description of methodology, reports de-
mographic and diagnostic data, in less detail than the cur-
rent table 3 and Supplementary Table S2 and for the
prodromal group in comparison to 2 comparison groups
reported here but not in comparison to SPD or FHR
groups. The second article focuses on improving the pos-
itive predictive value of conversion to psychosis within
the prodromal group,52 a topic not addressed in the
present report. The second article also presents a figure
comparing conversion rates in prodromals and NC sub-
jects, similar to the current figure 2 but without findings
on the SPD, FHR, and HSC groups. Otherwise there is
no overlap among the articles. Several of the subject
counts differ slightly between the first 2 articles and
the current one, as a result of identification and correc-
tion of internal inconsistencies in the database.
Results
Demographics
Sites contributedbetween50and205 subjects each (table 1).
Most subjects were followed at least 6 months (638/860,
74%). The large majority of prodromal patients qualified
for the diagnosis because of attenuated positive symptoms
(96%, table 2, first column, bottom row). Usually, this
was the sole prodromal syndrome diagnosed, although
GeneticRisk andFunctionalDeclineProdromal Syndrome
(GRD) was comorbid in a minority. Roughly 4% of the
prodromal sample met brief intermittent psychosis cri-
teria.GRDcriteriaweresatisfied in12%,withthis syndrome
usually comorbid with Attenuated Positive Symptom
Prodromal Syndrome. Only 6 patients (1.7%) met criteria
forGRDalone.Table3 shows somesmall groupdifferences
on gender, age, and race. Analyses adjusting for these
variables revealed no significant differences between pro-
dromal patients and comparison groups on education
oremploymentmeasuresexcept that theprodromalpatients
had completed slightly less schooling than NC subjects
and that the FHR subjects were less likely to be employed
than prodromal patients.
Fig. 2. Time to Conversion to Psychosis Among Subjects in the 5
Groups. Solid black line—prodromal patients (n 5 303, 89
converters). One patient in the prodromal group converted at 1006
days. Thin black line—normal comparison subjects (136,
0 converters, P < .001 vs prodromals). Dashed black line—help-
seeking comparison subjects (n 5 135, 3 converters, P < .001 vs
prodromals). Solid gray line—familial high-risk subjects (n 5 26,
0 converters, P < .001 vs prodromals). Dotted line—schizotypal
personality disorders (n 5 38, 8 converters, P 5 .230 vs
prodromals). PRO—prodromals, NC—normal comparison
subjects, HSC—help-seeking comparison subjects, FHR—familial
high-risk subjects, SPD—schizotypal personality disorder patients,
Con—cumulative number of converters, AR—number of at-risk
subjects remaining.
897
Validity of Psychosis Prodrome
Symptoms
Prodromal patients were distinguished from NC subjects
on the SOPS total score, every SOPS subscale, and every
SOPS item (table 4 and Supplementary Table S1). NC
group means were close to the SOPS minimum possible
score. HSC subjects had somewhat higher severity scores
on the SOPS, but the prodrome group was distinguished
from the HSC on the SOPS total score, all subscales, and
all but 3 individual items. Prodromal patients were dis-
tinguished from FHR subjects on available positive
symptom SOPS items; data were otherwise sparse.
The SPD-alone group received SOPS totals scores and
3 subscale scores that were similar to those from the pro-
drome group. Many of the individual SOPS item scores
were also similar, but the schizotypal group was rated
more severe than the prodrome group on several items
(disorganized speech, social anhedonia, emotional ex-
pression, odd behavior, and personal hygiene,
Table 2. Distribution of Prodromal Syndromes, n (%)
Syndrome Any APS Any BIPS Any GRD
Patients with complete data
One syndrome only 304/344 (88.4) 8/12 (66.7) 6/45 (13.3)
þAPS only — 2/12 (16.7) 37/45 (82.2)
þBIPS only 2/344 (0.6) — 1/45 (2.2)
þGRD only 37/344 (10.8) 1/12 (8.3) —
þAPS and BIPS — — 1/45 (2.2)
þAPS and GRD — 1/12 (8.3) —
þBIPS and GRD 1/344 (0.3) — —
Total complete data 344/359 (98.5) 12/359 (3.3) 45/359 (12.5)
Patients with missing data
Missing APS only — 0/14 (0.0) 0/45 (0.0)
Missing BIPS only 0/360 (0.0) — 0/45 (0.0)
Missing GRD only 16/360 (4.4) 2/14 (14.3) —
Missing both others 0/360 (0.0) 0/14 (0.0) 0/45 (0.0)
Total 360/377 (95.5) 14/377 (3.7) 45/377 (11.9)
Note: APS, Attenuated Positive Symptom Prodromal Syndrome; BIPS, Brief Intermittent Psychosis Prodromal Syndrome; GRD,
Genetic Risk and Functional Decline Prodromal Syndrome.





Overall F, v2, or
Wald (P)NC n = 196a HSC n = 198a FHR n = 40a SPD n = 49a
Gender, (%) males 62.1 45.9 63.6 42.5 67.3 23.3b (<.001)
Mean age (y) 18.2 18.7 16.1 19.4 16.1 13.8c (<.001)
Race, nonwhite (%) 22.0 36.2 29.3 42.5 28.6 17.5b (.002)
Mean highest grade 10.3 11.2 8.9 11.2 8.8 8.8d (<.001)
Current FT/PT school (%) 69.6 70.6 86.4 51.4 87.8 8.3e (.080)
Current FT/PT work (%) 21.6 22.8 14.1 0.0 6.1 13.8e (.008)
Parent college grade (%) 66.2 75.0 63.2 59.5 67.4 6.7e (.154)
Note: FT/PT, full-time or part-time.
aData are complete for gender, age, and race. Due to missing data, the actual sample size for other measures varied: 302–375 for
prodromal patients, 167–193 for normal comparison (NC) subjects, 182–198 for help-seeking comparison (HSC) subjects, 21–37 for
familial high-risk (FHR) subjects, and 46–49 for schizotypal personality disorder (SPD) patients. Italicized values are significantly
lower than for the prodromal group; underlined values are significantly higher than for the prodromal group; values neither italicized
nor underlined are not significantly different from the prodromal group.
bIndicates that statistic value is v2.
cIndicates that statistic value is F from analysis of variance.
dIndicates that statistic value is F from analysis of covariance, adjusting for gender, age, and race.
eIndicates that statistic value is Wald from logistic regression, adjusting for gender, age, and race.
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Supplementary Table S1) and the disorganization sub-
scale (table 4).
Functional Status
Prodromal patients were impaired relative to normal
and FHR groups on all measures of current functioning
(table 5). The mean GAF score was 46. HSC subjects
were less impaired than prodromal patients on some
measures of current functioning, whereas schizotypals
were as impaired as prodromal patients on 3 measures
and more impaired on social functioning.
Premorbid Adjustment Scale scores distinguished
prodromal patients from NC subjects but not from
HSC or FHR subjects. Schizotypal patients showed
poorer premorbid adjustment than prodromal patients,
beginning in early adolescence.
Diagnostic Comorbidity
DSM-IV diagnostic comorbidity with the prodrome at
baseline was common: 69% had one or more mood/anx-
iety diagnoses, 25% had one or more substance abuse or
dependence diagnoses, and 44% had one or more Axis II
Table 4. Group Comparisons on the SOPS Symptom Measures
Dependent Measures Prodromal n = 377a
Comparison Group
Overall F (P)NC n = 118a HSC n = 198a FHR n = 2 SPD n = 49a
SOPS total 38.4 2.1 23.5 0.5 39.2 206.8 (<.001)
SOPS positive 11.9 0.7 4.6 0.0 10.7 277.9 (<.001)
SOPS negative 12.1 0.6 9.9 0.5 13.7 79.5 (<.001)
SOPS disorganization 6.5 0.3 3.5 0.0 7.9 92.9 (<.001)
SOPS general 8.0 0.4 5.5 0.0 6.6 83.0 (<.001)
Note: General linear models adjusted for age, gender, and race. Post hoc contrast findings are illustrated as for table 3. SOPS, Scale of
Prodromal Symptoms.
aDue to missing data, the range of actual sample sizes for each group is prodromal 360–377, normal comparison (NC) subjects 117–118,
help-seeking comparison (HSC) subjects 189–198, and schizotypal personality disorder (SPD) subjects 48–49.
Table 5. Group Comparisons on the Functioning Measures
Dependent Measures Prodromal n = 377a
Comparison Group
Overall F (P)NC n = 139a HSC n = 198a FHR n = 38a SPD n = 49a
Social function 6.2 8.6 6.0 7.0 5.3 102.4 (<.001)
Role performance 6.1 8.7 6.2 6.9 6.0 70.9 (<.001)
Psychological
function
5.7 9.0 6.3 7.0 5.8 316.4 (<.001)
Global function
current
46.4 87.0 53.6 71.1 47.5 162.7 (<.001)
PAS–child 0.75 0.87 0.72 0.76 0.62 13.4 (<.001)
PAS–early adolescent 0.66 0.84 0.62 0.70 0.50 30.9 (<.001)
PAS–late adolescent 0.64 0.88 0.62 0.73 0.51 21.5 (<.001)
PAS–adult 0.65 0.96 0.65 0.80 0.28 16.2 (<.001)
PAS–total 0.68 0.85 0.63 0.73 0.53 41.2 (<.001)
Note: General linear models adjusted for age, gender, and race. Post hoc contrast findings are illustrated as follows: values significantly
more impaired than the prodromal group are underlined, values significantly less impaired than the prodromal group are italicized.
Social, role, and psychological functioning scales ranged from 0 to 10 (highest).42 Global functioning ranged from 0–100 (highest).39
Premorbid Adjustment Scale (PAS) values reflect the proportion of optimal adjustment, ranging from 0.00 to 1.00 (highest).40,41
aDue to missing data, the range of actual sample sizes for each group is social, role, and psychological functioning 371–377 for
prodromal patients, 137–139 for normal comparison (NC) subjects, 196–198 for help-seeking comparison (HSC) subjects, and no
missing data for familial high-risk (FHR) subjects or schizotypal personality disorder (SPD) subjects; for Global Assessment of
Functioning Scale 368 for prodromal patients, 57 for NC, 167 for HSC, no missing data for FHR, and 47 for SPD; for PAS across
subscales 101–326 for prodromal patients, 34–120 for NC, 14–147 for HSC, 18–37 for FHR, and 4–37 for SPD.
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diagnoses (Supplementary Table S2). Diagnostic comor-
bidity rates for many disorders distinguished prodromal
patients from normals. Lifetime major depression and
dysthymia rates were higher among prodromal patients
than among HSC subjects, and anxiety disorder and
social phobia rates were higher among prodromal
patients than among schizotypals. Lifetime substance
abuse diagnoses did not distinguish prodromal patients
from FHR, SPD, or HSC groups. There were higher
proportions of paranoid, schizoid, and avoidant per-
sonality disorders among schizotypals than among pro-
dromal patients. HSC group membership excluded
subjects with SPD by definition (figure 1).
Family History
Family history of psychosis distinguished the prodromal
group from the HSC group for illness density and from
the schizotypal group on 2 measures (table 6). Family
history of nonpsychotic psychiatric illness distinguished
the prodromal group from the NC subjects on all meas-
ures and from the HSC group on illness density (table 6).
The FHR group was defined by first-degree family his-
tory of psychosis and the NC group by its absence.
Course of Illness
Time-to-event curves for conversion to psychosis are
shown in figure 2. Kaplan-Meier analyses show that
40% of prodromal patients converted to fully psychotic
illness during 2.5 years of follow-up. Corresponding rates
for NC, HSC, FHR, and SPD subjects were 0%, 4%, 0%,
and 36%, respectively. Cox regression comparing groups
with nonzero conversion rates distinguished prodromal
patients from HSC subjects (P < .001) but not from
SPD subjects (P = .230). Fisher exact tests showed that
prodromals converted significantly more often than
FHR subjects and NC subjects (both P < .001). Pooling
all the nonprodromal subjects into a single comparison
group, the sensitivity of a baseline prodromal diagnosis
for conversion to psychosis was 89.0% (89/100), and the
specificity was 60.2% (324/538).
DSM-IV diagnoses of converting patients are shown in
table 7 by baseline status. A third of these diagnoses are
missing, in cases where the site learned of conversion
through telephone or collateral sources, and the subject
could not be scheduled for structured interview. Conver-
sion diagnoses in the former prodromal patients were
schizophrenia-spectrum psychoses in 56%, affective psy-
choses in 10%, and other psychoses, principally psychosis
not otherwise specified (NOS), in 34%. The diagnostic
distribution of the small number of converters from
outside the prodromal group does not differ conspicu-
ously from the diagnostic distribution of the prodromal
converters.
Discussion
The principal finding of the present study is that the SIPS
structured interview identifies a prodromal risk syn-
drome that is generally distinct from NC, HSC, and
FHR groups across symptom, functioning, comorbidity,
family history, and course of illness domains (table 8).
Clear and compelling differences between a prodrome
sample and NC subjects are certainly necessary to estab-
lish the validity of a prodromal diagnosis. Relatively few
prior studies of prodromal patients in the past decade






F (P)NC n = 190a HSC n = 176a FHR n = 40a SPD n = 43a
Family history of psychotic illness
Definite in FDR (%)b 18.6 0.0 10.8 100 4.7 220.9 (<.001)
Definite in FDR or SDR (%)b 33.0 1.8 26.2 100 10.5 197.7 (<.001)
Proportion FDR definiteb 7.0 0.0 3.8 27.2 1.2 36.2 (<.001)
Family history of nonpsychotic
psychiatric illness
Definite in FDR (%)b 48.0 15.3 40.8 22.5 38.5 56.1 (<.001)
Definite in FDR or SDR (%)b 66.1 37.2 64.1 90.9 75.0 32.9 (<.001)
Proportion FDR definiteb 23.0 6.3 17.0 5.3 19.2 11.1 (<.001)
Note: P values and statistic values are adjusted for gender, age, and race. Statistic value is F for diagnostic group term from general
linear models for continuous measures and v2 from logistic regression for categorical measures. Post hoc test results are illustrated as
for table 3.
aSample size shown is for definite psychosis in first-degree relatives (FDRs). Sample size across other measures was 303–333 for
prodromals, 121–189 for normal comparison (NC) subjects, 164–174 for help-seeking comparison (HSC) subjects, 11–40 for familial
high-risk (FHR) subjects, and 36–42 for schizotypal personality disorder (SPD) subjects. SDR indicates second-degree relatives.
b‘‘%’’––The number of subjects with one or more relatives qualifying; ‘‘proportion’’––mean density of illness, the average of the
proportion of each subject’s relatives who qualify.
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have taken this necessary step in any domain.12,16,24 His-
torically, attempts to identify prodromal patients using
theDiagnostic and StatisticalManual ofMental Disorders
(Third Edition Revised) checklist foundered on the in-
ability of the checklist to distinguish patients from non-
patients.53 Our findings based on current methods of
prodromal diagnosis establish the distinction from NC
subjects convincingly.
Although distinction from a NC group is necessary,
this demonstration is by no means sufficient. A more
Table 8. Summary of Differences From Prodromal Patients
Domain (Location of Details)
Comparison Group
NC HSC FHR SPD
Positive symptom severity (table 3) YY Y YY 0
Negative symptom severity (table 3) YY Y . [
Functioning at baseline (table 5) YY Y YY [
Premorbid adjustment (table 5) YY 0 0 [[
Affective comorbidity (supplementary table S1) YY Y . 0
Substance disorder comorbidity (supplementary table S1) YY 0 0 0
Axis II comorbidity (supplementary table S1) YY 0 . NA
Family history of psychosis (table 6) NA Y NA Y
Family history of nonpsychotic illness (table 6) YY Y Y 0
Conversion to psychosis (figure 2) YY YY YY 0
Note: YY indicates that the comparison group was significantly less impaired than prodromal patients on all or most measures, Y
indicates significantly less impaired on some measures or numerically less impaired on the sole measure in the domain, 0 indicates
nonsignificance on all measures or significantly more impaired on some measures but significantly less impaired on others or
numerically similar on the sole measure in the domain, [ indicates that comparison group was significantly more impaired than
prodromal patients on some measures or numerically more impaired on the sole measure in the domain, [[ indicates significantly more
impaired than prodromal patients on all or most measures, . indicates that data were sparse. NA indicates that groups differed from
prodromal patients by definition. NC, normal comparison; HSC, help-seeking comparison; FHR, familial high risk; SPD, schizotypal
personality disorder.
Table 7. DSM-IV Diagnoses of Converters by Baseline Diagnosis
Baseline Diagnosis
DSM-IV diagnosis at conversion Prodromal SPD HSC
295.10 schizophrenia, undifferentiated 3 (5.1%)
295.30 schizophrenia, paranoid 4 (6.8%)
295.90 schizophrenia, undifferentiated 8 (13.6%) 4 (57.1%)
295.70 schizoaffective disorder 6 (10.2%) 2 (28.6%)
295.40 schizophreniform disorder 12 (20.3%)
Subtotal schizophrenia-spectrum psychoses 33 (55.9%) 6 (85.7%)
296.04 bipolar I, single mania, with psychosis 1 (50.0%)
296.44 bipolar I, MRE manic, with psychosis 5 (8.5%)
296.64 bipolar I, MRE mixed, with psychosis 1 (1.7%)
296.34 recurrent depression, with psychosis 1 (14.3%)
Subtotal affective psychoses 6 (10.2%) 1 (14.3%) 1 (50.0%)
297.1 delusional disorder 2 (3.4%)
298.8 brief psychotic disorder 2 (3.4%)
298.9 psychosis NOS 16 (10.2%) 1 (50.0%)
Subtotal other psychoses 20 (33.9%) 1 (50.0%)
Total conversion with DSM-IV diagnoses 59 (100.0%) 7 (100.0%) 2 (100.0%)
Missing DSM-IV diagnoses 30 (33.7%) 1 (12.5%) 1 (33.3%)
Total conversions to psychosis 89 (100.0%) 8 (100.0%) 3 (100.0%)
Note: DSM-IV, Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition); SPD, schizotypal personality disorder; HSC,
help-seeking comparison; MRE, most recent episode.
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rigorous test of syndromal validity would be provided by
a comparison group from the same referral pool: those
who were clinically referred for prodrome evaluation
but who did not meet prodrome criteria on interview.
We identify such patients here as ‘‘HSC subjects.’’ Few
previous studies have compared prodromal patients
with HSC subjects,4,16–18,21,26 and these either limited
themselves to 1 or 2 measurement domains4,17,18,21,26
or had a small prodromal sample.16 The multiple differ-
ences from HSC subjects on most cross-sectional varia-
bles, as well as the profound differences in conversion
outcomes, provide very strong evidence of validity of
the prodromal risk syndrome.
FHR subjects had historically offered the available re-
search paradigm with the highest risk of psychosis, prior
to the advent of prospective prodromal research. Prodro-
mal patients were robustly distinguished from FHR sub-
jects on all measures of current functioning and on risk of
transition to psychosis over the near term. Although pro-
dromal patients and FHR subjects are quite distinct on
theoretical grounds, this is the first study to our knowl-
edge to make empirical comparisons between these
groups.
The symptoms of the psychosis prodrome and the
symptoms of SPD are similar on a cross-sectional basis.54
The 2 syndromes are, however, clearly delineated by def-
inition: Prodromal patients must show progression of ill-
ness in the past year while SPD patients may have been
stably ill; SPD patients must exhibit symptoms in at least
5/9 areas while prodromal patients may exhibit fewer
symptoms. Clear delineation of the 2 syndromes also per-
mits them to co-occur. In our sample, 26% of prodromal
patients met SPD criteria, and 67% of schizotypally diag-
nosed patients met prodrome criteria.
Because the 2 syndromes share membership in the psy-
chosis-spectrum group of conditions, however, the inter-
pretation of comparisons between the 2 groups does not
speak as straightforwardly as the previous comparisons
to issues of discriminant (or convergent) validity. These
comparisons are nevertheless of interest. The final rate
of transition to psychosis in patients with SPD alone
was similar to that in the prodromal group (figure 2).
Thus, our results suggest that SPD in adolescents and
young adults may be like the prodrome in that it may
also constitute an identifiable risk syndrome for psychosis.
The conclusion that SPD can constitute a risk syn-
drome for psychosis does have some precedents. While
SPD has often been conceptualized as a stable condition,
this stability may primarily apply to older samples.
Others have also reported that adolescents and young
adults with SPD are at substantial risk of developing psy-
chosis,55,56 although neither of these studies removed
comorbid prodromal patients from the SPD analysis
group as in the current analyses.
SPD in adolescents and young adults may capture indi-
viduals with a more gradual progression of illness than
the prodrome criteria. Evidences in the current study con-
sistent with such speculation are the greater impairment
of premorbid adjustment in the SPD-alone group than
the prodromal group, the lack of dramatic progression
in the year before baseline in the SPD-alone subjects
(by virtue of their not meeting prodrome criteria), and
the suggestion in figure 2 that conversions occurred
somewhat later in the patients with SPD alone than in
prodromals. A factor that may contribute to the possibly
later conversion in the SPD group is their younger age at
ascertainment because more time would be required to
enter the age of maximum risk.
Strengths and Limitations
The primary strength of the study is the large sample size
of well-characterized patients meeting prodrome criteria:
Three hundred seventy-seven is 2–3 times as large as the
next largest reported samples.8,21,25,26 An additional
strength is the use of the SIPS for evaluating subjects.
Psychometric properties for this instrument have been fa-
vorable,4,5,20,33,34 and reliability in its use was established
cross-site.
An important potential limitation is that comparisons
involving symptom severity, family history, and func-
tional decline could be viewed as tautological because
these domains contribute to making a prodromal
diagnosis. However, several considerations suggest that
these comparisons reflect discriminant validity largely
independently from definitional issues. First, only 1.7%
of the prodromal sample qualified for a prodromal
diagnosis based solely on family history and functional
decline.30 Removal of this small number of subjects
would have little impact on the family history findings
in table 6 or the functional findings in table 5. Second,
only positive symptoms contribute to the prodrome
definition, and the pattern of the data for the nonpositive
symptoms is similar to that for the positive symptoms
(table 4). Lastly, the contribution of severity of positive
symptoms to a prodromal diagnosis is not a deterministic
one, as the prodromal syndromes defined by positive
symptoms require symptom frequency and recent symp-
tom change criteria in addition to symptom severity.
Thus, prodromal patients are not required by definition
to have more severe positive symptoms than HSC
subjects.
Other limitations stem from the study data having been
originally collected through independent protocols. Such
limitations include the variability of statistical power
across pairwise comparisons, the absence of symptom
data other than those from the SOPS, methods of recruit-
ment and evaluation that varied somewhat, the need to
estimate SOPS data for most FHR subjects, the uncertain
agreement between the Axis II interviews employed, and
our inability to subdivide family history of nonpsychotic
illness into finer-grained categories.
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Because the large majority (table 2) of the prodromal
patientsmet only 1 of the 3 sets of prodrome criteria, those
for attenuated positive symptoms, another limitation is
that the current evidence of syndromal validity applies al-
most exclusively to this common prodromal syndrome.
Thecurrentdatadonotprovideanadequate testof theval-
idity of the other 2 less common prodromal syndromes
(brief intermittent frank psychosis and genetic risk with
functional decline).
A further limitation is that the current data do not ad-
dress the probability of diagnostic changes after baseline
other than conversion. For example, initial HSC subjects
or schizotypal patients may meet prodrome criteria dur-
ing follow-up, and FHR subjects or prodromal patients
may develop schizotypal personality during follow-up.
Lastly, the aim of the current prodromal definition
focused on positive symptoms was to identify patients
relatively late in an ongoing prodrome. Retrospective
work suggests that identifiable negative, anxiety, and de-
pressive symptoms may precede the onset of attenuated
positive symptoms during the prodrome,57 but the spec-
ificity of such early symptoms in prospectively identifying
patients whowill transit to psychosis remains an area that
requires further investigation. Some self-perceived men-
tal functioning deficits, known as ‘‘basic symptoms,’’58
may also provide a means to identify patients as prodro-
mal before the onset of attenuated positive symptoms.
Specific Psychotic Outcomes of the Prodromal Risk
Syndrome
Following usual practice among prodromal research clin-
ics, this article reports on conversion to psychosis, includ-
ing cases of affective psychosis, rather than conversion
more narrowly to schizophrenia. Conversions to affective
psychosis from the prodrome represented a substantial,
albeit a minority, proportion (10%, table 7). This propor-
tion is in general agreement with previous reports.8–10,19
The initial reason that prodromal clinics reported con-
version to the broader psychosis construct related to the
perceived relative instability of specific diagnoses in early
first-episode psychosis.3 Recent studies have confirmed
that the initial DSM-IV diagnosis is somewhat unstable
in the first episode.59–65 The large majority of first-
episode affective psychosis diagnoses in these studies
were stable, however, with 82% of the 488 patients again
receiving affective psychosis diagnoses at 12- to 36-month
follow-up. Based on these previous findings, many of our
affective psychosis converters might remain cases of
affective psychosis if further follow-up were available.
Thus, the preliminary conclusion is that affective psy-
choses may share with schizophrenia-spectrum psychosis
a prodrome characterized by attenuated positive symp-
toms. Similarly, recent work describing prodromal symp-
toms for mania found attenuated positive symptoms
more predictive of psychotic mania than nonpsychotic
mania.66 This preliminary conclusion of a similar pro-
drome in schizophrenic and affective psychosis is consis-
tent with genetic epidemiology and molecular genetic
data suggesting a similarity between schizophrenic and
affective psychoses.67–72 Additional emerging data
from the NAPLS collaboration suggest that the converse
may be true as well: The prodromal risk syndrome for
psychosis may not confer high specific risk for non-
psychotic affective disorder. Nonpsychotic mania at
follow-up was more common in the HSC subjects than
in the prodromal group.73
Comorbidity in the Prodromal Risk Syndrome
The common comorbidity of established DSM-IV diag-
noses in prodromal patients, reported previously,17 is not
dissimilar to the range of comorbidity reported for
schizophrenia itself, when no diagnostic hierarchy is im-
posed as in the current study.74–82 The presence of the
comorbid diagnoses should not rule out consideration
of a prodrome diagnosis if the comorbid diagnoses do
not account for the symptoms, distress, and functional
impairment that the patient experiences.
Next Steps for the Prodromal Risk Syndrome
The current construct validity findings comprise part of
the work necessary to establish a fully valid diagnosis;
however, several other questions remain which will
require additional studies.
One of the most important questions is whether the
prodromal diagnosis can be refined so as to increase
the proportion of cases that convert to psychotic illness.
Our group has focused on this question elsewhere.52 We
found that the addition of 3 clinical severity criteria to the
current prodromal diagnostic criteria can increase the
proportion of converting patients to 80%. Unfortunately,
imposing 3 additional severity criteria also leads to a sub-
stantial loss of sensitivity, such that 70% of converting
cases are now falsely predicted not to convert. Thus, fur-
ther studies are needed to refine the prodromal diagnosis,
both to replicate that more stringent criteria continue to
predict conversion in a high proportion of individuals
and to determine whether other revisions to the criteria
could substantially restore sensitivity.
Because only 89% of the converters in our clinically re-
ferred sample had met prodrome criteria at baseline, an-
other question is whether to revise prodrome criteria to
try to capture the 11% of converting cases that were not
diagnosed as prodromal at baseline. Most of these sub-
jects met schizotypal criteria, but a few did not. Some
cases may have met prodrome or SPD criteria at an in-
tervening time point, as discussed earlier.
An additional challenge for this field is to characterize
the outcomes of a prodromal diagnosis more rigorously.
Fully formed psychosis is likely not to be the only
psychosis-spectrum outcome. Developing psychosis
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captured as an initial diagnosis of prodromemay stabilize
at a subsyndromal or ‘‘schizotypal’’ level. Such outcomes
are worthy of increased attention. Similarly, we need to
know more about how often and how completely appar-
ently ‘‘prodromal’’ symptoms remit spontaneously and
how often nonpsychotic diagnoses such as depression
newly emerge or persist.
Another important question centers on the effect of the
patient pool from which evaluations for the prodrome are
drawn. Recent reports of a declining rate of conversions to
psychosis (16% at 2 y26 compared with 30% in the present
sample, 12% at 12 mo25 compared with 22% in the present
sample) have emphasized the possible role of referral of
subjects whose ‘‘prodromal’’ symptoms are not associated
with distress, help seeking, or reduced functioning but are
only incidental to help-seeking behavior associated with
other psychiatric syndromes.25,26 This interpretation is
consistent with a well-documented literature on the fre-
quency of nonpathologic and asymptomatic self-reported
psychotic symptoms in the general population.83–88 Future
studies on subsequent course should address the impact of
imposing additional phenomenological requirements such
as distress, help seeking, and/or loss of functioning asso-
ciated with the psychotic-like symptoms. Inclusion of in-
dices of disturbance of the basic sense of self could
potentially increase conversion rates as well.89 In the
meantime, the apparent recent attraction of higher pro-
portions of low-risk patients to prodromal diagnostic eval-
uation stresses the importance of investigating low-risk
treatment options, such as cognitive therapy9 and medica-
tions other than antipsychotics.
Future studies should also address what proportion
of the general population actually receive prodromal
diagnoses on specialized structured interviews like the
SIPS and what are the psychosis conversion rates in
this group. The current normative data suggest that
the proportion will be quite low, but NC subjects are pre-
screened for health and thus cannot estimate prevalence
in the general population. Previous epidemiologic stud-
ies83–88,90 unfortunately cannot address these questions
directly. In the meantime, use of prodromal diagnostic
assessments should be reserved for patients clinically re-
ferred specifically because of concerns about psychosis.
Conclusions
In this article, we have demonstrated that prodromal
patients are not only distinguished from 3 comparison
groups on risk for psychosis but also are more symptom-
atic and more impaired functionally relative to these
groups. This dual status of patients meeting prodromal
criteria, ie, both currently symptomatic and at risk for
getting worse in the future,91 is captured by our use of
the term ‘‘risk syndrome.’’ Our finding of an average
GAF score in the 40s is supported by preliminary studies
from other samples demonstrating that these young
people have impairments more severe than treated
patients who had already become psychotic.3,6 Even
without concerns about conversion, such impairment rai-
ses questions about need for treatment. Determining
valid criteria for this syndrome should contribute to
the development of appropriate treatments.
At some point during the research process, the
diagnosis of the prodromal risk syndrome for psychosis
may be ready for acceptance and codification for clinical
use by psychiatric professional societies, such as in the
DSM of the American Psychiatric Association. The pres-
ent data allow the research diagnosis of the psychosis
prodrome to move in that direction. Formal acceptance
andcodificationneednot imply thatprodromaldiagnostic
criteria are ‘‘set into stone.’’ Rather, the prodromal diag-
nosis should be subject to a continuous process of testing
and refinement as are the established DSM diagnoses.
Should the prodromal risk syndrome for psychosis
eventually be officially sanctioned, it will differ from
many of the diagnoses currently used in DSM-IV in
that it will be a ‘‘transitional’’ diagnosis, intended to
be used for a limited period of time during the patient’s
life course and to be supplanted by otherDSM diagnoses
later, should their criteria be met. As a transitional diag-
nosis, the prodromal risk syndrome for psychosis would
be akin to ‘‘mild cognitive impairment’’ as a prodromal
risk syndrome for Alzheimer disease92 or ‘‘clinically iso-
lated syndromes’’ as prodromal risk syndromes for mul-
tiple sclerosis.93 Apart from these medical examples,
there is already some precedent in DSM-IV for transi-
tional diagnoses that are expected over time either to re-
mit or to progress or to be reclassified but not to endure.
Examples in the psychotic disorders section include pro-
visional cases of schizophreniform disorder and some
cases of psychosis NOS. The concept of transitional di-
agnoses has much in common with proposals for ‘‘stag-
ing’’ psychiatric illness94 and proposals for considering
a developmental perspective in classifying disorders for
Diagnostic and Statistical Manual of Mental Disorders
(Fifth Edition) (DSM-V).95,96
A DSM-V diagnosis of prodromal risk syndrome is
supported by the evidence of validity presented here
and by the patients’ current need for treatment in addi-
tion to the high probability of illness progression. On the
other hand, risks associated with a prodromal diagnosis
must be taken into account as well.19,97,98 Patients will be
exposed to risks of any medications used, as well as the
possibility of stigma or even discrimination from friends,
families, community organizations, or insurance compa-
nies. Similar risks come with any diagnosis, but they be-
come even more salient when a proportion of the patients
are expected to remit spontaneously without treatment.
Moreover, if a process of widening clinical indications
for treatment without waiting for the results of well-
designed clinical trials were accelerated by a DSM-V
prodromal risk syndrome diagnosis, this process could
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increase patient exposure to risk. Lastly, sanctioning a
prodromal diagnosis could contribute to the diagnosis
being made inappropriately among populations where
the criteria have not been carefully studied, and hence,
the outcomes cannot be predicted, such as asymptomatic
or general clinical populations.
Many of the risks of a prodromal diagnosis detailed
above are aggravated by the paucity of research on out-
comes and interventions in these patients. Inclusion of
the prodromal risk syndrome in DSM-V is likely to stim-
ulate research on these questions that in turn would reduce
the risks of a prodromal diagnosis and enhance the benefits.
Lastly, the problem of well-meaning clinical practice racing
ahead of the research evidence is occurring even in the ab-
sence of a DSM prodromal risk syndrome diagnosis. It is
not certain that a DSM-V diagnosis would accelerate the
process, and itmay actually ameliorate it bymaking criteria
available that indicate who is not likely to be prodromal.
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